Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615196 | 0.85 | CES2 (0.37) | CES2CES1SLC6A2ERN1HTR1A | |
| SCHEMBL28991597 | 0.83 | KDM4E (0.32) | KDM4EMAPTCRHBPCRHR2PREP | |
| SCHEMBL29112947 | 0.81 | ALDH1A1 (0.33) | KDM4EMAPTCRHBPCRHR2ALDH1A1 | |
| SCHEMBL23272973 | 0.78 | CA2 (0.36) | KDM4EMAPTCES2CES1CYP3A4 | |
| SCHEMBL29263394 | 0.76 | CA1 (0.35) | CES2CES1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL31096182 | 0.76 | HTT (0.33) | CES2CES1ERN1 | |
| SCHEMBL28855192 | 0.76 | HTR1A (0.40) | SLC6A2HTR1ASLC6A4 | |
| SCHEMBL4098184 | 0.73 | KMT2A (0.46) | KDM4EMAPTCYP3A4ALDH1A1HPGD | |
| SCHEMBL29158156 | 0.73 | ERN1 (0.53) | CES2CES1ALDH1A1HPGDTDP1 | |
| SCHEMBL30050189 | 0.73 | KMT2A (0.46) | KDM4EMAPTCYP3A4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497396-B2 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| EP-4253376-B1 | SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20240325394-A1 | SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| EP-4253376-A1 | SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-116003405-A | Inhibitors of KRAS G12C and methods of use thereof | 美国安进公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| EP-3978490-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-04-06 | — | — | EP | disclosed |
| CN-111051306-A | Inhibitors of KRAS G12C and methods of use thereof | 美国安进公司 | 2020-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, NRAS, GNAQ | KDM4E 3400/4885MAPT 4111/4885CRHBP 2539/4885 |
| US-20240325394-A1 | SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, NRAS, HRAS | KDM4E 4429/4885MAPT 2247/4885CRHBP 3085/4885 |
| US-12497396-B2 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | KRAS, NRAS, GNAQ | KDM4E 3994/4885MAPT 4113/4885CRHBP 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.